AbbVie Inc. reported second-quarter 2026 financial results with net revenues of $16.99 billion, a 10.2 percent increase, and adjusted diluted EPS of $3.65, up 22.9 percent. The company announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion to expand its immunology portfolio, with the transaction expected to close in the third quarter of 2026. AbbVie updated its full-year adjusted diluted EPS guidance range downward from $13.91-$14.11 to $13.87-$14.07, reflecting a $0.14 per share dilutive impact from the acquisition and $0.58 in acquired IPR&D expenses. Key product highlights included Skyrizi revenues of $5.5 billion and Rinvoq revenues of $2.5 billion. AbbVie Inc. operates in the pharmaceutical industry, discovering and delivering innovative medicines across immunology, neuroscience, oncology, and aesthetics.

AbbVie reported that second-quarter 2026 GAAP and adjusted non-GAAP earnings will include a pre-tax acquired IPR&D and milestones expense of $291 million, reducing diluted earnings per share by $0.17. Consequently, the company provided updated guidance for the second quarter of 2026 with an adjusted diluted EPS range of $3.57 to $3.61. The full-year 2026 adjusted diluted EPS guidance range, incorporating this expense, is now $13.91 to $14.11. AbbVie is a biopharmaceutical company that discovers, develops, and markets advanced therapies.

On June 22, 2026, AbbVie Inc. and Apogee Therapeutics, Inc. announced a definitive agreement for AbbVie to acquire Apogee. The transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032. The acquisition includes Apogee's pipeline assets, specifically zumilokibart (APG777) and APG273. AbbVie operates in the biopharmaceutical industry, developing and marketing advanced therapies for complex health conditions.

AbbVie's 2026 Annual Meeting resulted in the successful election of directors and ratification of executive compensation, though shareholders rejected proposals to eliminate supermajority voting and mandate an independent board chair. The failure of the independent chair proposal, which received more votes against than in favor, signals persistent investor interest in governance reform. These results indicate that while the current management structure remains intact, there is significant shareholder pressure regarding board independence.

AbbVie Inc. has announced its financial results for the first quarter ended March 31, 2026. This release is a critical event for investors as it provides the company's most recent quarterly performance metrics and updates on its financial health.

AbbVie updated its 2026 earnings guidance to include an expected $744 million pre-tax charge for acquired IPR&D and milestone expenses in the first quarter. This expense will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.41 for the quarter, resulting in a revised full-year 2026 adjusted diluted EPS guidance range of $13.96 to $14.16. This update is significant for investors as it clarifies the immediate impact of recent research and development investments and collaborations on the company's profitability.